RxDoctor Payments DataLook up a doctor →

Millie Long, MD

Internal Medicine · Chapel Hill, NCNPI 1336101914

Payments from drug & device makers

$1,162,273in general payments, 2019–2025

Across 406 payments — averaging $2862.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$477K
  • AbbVie$310K
  • Sanofi US Services Inc.$85K
  • Eli Lilly$72K
  • Janssen Research & Development, LLC$55K
  • Johnson & Johnson$53K
  • plus $111K from 19 others
$34,220in research payments, 2019–2025

Across 30 payments — averaging $1140.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$29K
  • AbbVie$5K

What the payments were for

  • Consulting fees$240,04764%
  • Speaking & faculty fees$102,19927%
  • Travel & lodging$26,2797%
  • Food & beverage$5,2461%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,162,273 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,770
Medicare patients
71
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab67$1,806,872
GattexTeduglutide18$843,342
Skyrizi On-BodyRisankizumab-Rzaa25$492,127
Humira(Cf) PenAdalimumab20$285,261
RinvoqUpadacitinib30$234,682
SimponiGolimumab12$148,113
XeljanzTofacitinib Citrate22$127,164
XifaxanRifaximin18$55,958
Mesalamine25$9,918
Colestipol Hcl29$6,949
Vancomycin Hcl17$6,835
Mesalamine ErMesalamine11$6,555
CholestyramineCholestyramine (With Sugar)18$2,733
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine37$2,138
Pantoprazole Sodium40$1,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$52,614$1,954,98579 claims
Takeda Pharmaceuticals U.S.A., Inc.Gattex$35,549$843,34218 claims
AbbVieRinvoq$310,154$234,68230 claims
PfizerXeljanz$476,917$127,16422 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$5,530$55,95818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →